Fig. 2. Small molecule glycomimetics prevent β-GP-induced ALP activity and mRNA abundance in human VSMCs. (A-C) ALP activity was determined at days 4, 7 and 10. Glycomimetics C1-C4 significantly inhibit β-GP-induced ALP activity. (D) ALP mRNA abundance was significantly up-regulated after 7 days of β-GP treatment and was inhibited by C1-C4. Results are mean ± SEM; n = 6-10, and experiments were repeated at least three times independently. ***P<0.001. β-GP, β-glycerophosphate; ns, non-significant.